Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Mouse (tested or 100% immunogen sequence identity)
Specificity and Use
MAPK7 / ERK5 antibody was raised against synthesized peptide derived from residues 334-349 of the human ERK5/BMK1 protein. Full-length ERK5/BMK1 has a Mr of ~88 kD, however, truncated versions of ~30-35 kD have also been observed.
Human MAPK7 / ERK5
Optimal concentration should be evaluated by serial dilutions. For Western blot applications, we recommend using the antibody at 0.1-1.0 ug/ml.
PBS, 0.08% Sodium Azide
Store at -70°C. Aliquot to avoid freeze/thaw cycles.
ERK5, a MAPK type protein kinase, mediates growth factor stimulated cell proliferation and muscle cell differentiation. ERK5 differs from other MAP kinases in that it contains a unique loop-12 region within the protein kinase domain which is followed by an extensive C-terminal tail with sequences indicating that it may be targeted to the cytoskeleton. ERK5 is phosphorylated and activated by MEK5 in response to osmotic shock, growth factors and oxidant stress.
Western blot of ERK5 antibody (LS-C140530) on HEK293 cells transfected with human ERK5 protein. Incubated with 0.15-1.5 ug/ml of ERK5 antibody and visualized with goat anti-rabbit IgG antibody conjugated to alkaline phosphatase.
Requested From: United States
Date Requested: 2/22/2017